| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.12.085 |
| P8608 | Fatcat ID | release_rjdexthbzvex7gjanin5nyb4ze |
| P698 | PubMed publication ID | 15774780 |
| P50 | author | Eva Szabo | Q69483163 |
| Len Neckers | Q89479068 | ||
| P2093 | author name string | Jean L Grem | |
| Richard H Wilson | |||
| Chris H Takimoto | |||
| Frank Grollman | |||
| Rebecca Thomas | |||
| Elizabeth Agnew | |||
| J Michael Hamilton | |||
| Geraldine Morrison | |||
| Louise Grochow | |||
| Xiao-Du Guo | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 1885-1893 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors | |
| P478 | volume | 23 |
| Q38706293 | 17-AAG and Apoptosis, Autophagy, and Mitophagy in Canine Osteosarcoma Cell Lines |
| Q34158824 | 17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. |
| Q42717415 | 17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells |
| Q40492036 | 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species |
| Q83205302 | 47th Annual Meeting of the American Society of Hematology Atlanta, GA |
| Q34595727 | A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues |
| Q39943622 | A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells |
| Q37103825 | A highly invasive human glioblastoma pre-clinical model for testing therapeutics |
| Q37334829 | A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy |
| Q37718291 | A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. |
| Q33397124 | A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas |
| Q36316817 | A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. |
| Q37338986 | A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer |
| Q48474924 | A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma |
| Q34898930 | A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer |
| Q37120694 | Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells |
| Q27022514 | Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers |
| Q37256846 | Androgen receptor: role and novel therapeutic prospects in prostate cancer |
| Q35991786 | Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii |
| Q40380103 | Antimyeloma activity of heat shock protein-90 inhibition. |
| Q40178192 | Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses |
| Q36118820 | BUB1 mediation of caspase-independent mitotic death determines cell fate |
| Q35859205 | Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells |
| Q62645453 | Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors |
| Q42409009 | Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention |
| Q33440318 | Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma |
| Q38103907 | Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives |
| Q38987771 | Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors |
| Q36773464 | Drug insight: role of the androgen receptor in the development and progression of prostate cancer |
| Q28254233 | Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics |
| Q35350578 | Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET |
| Q37204596 | Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials |
| Q36758596 | Emerging drugs for the treatment of soft tissue sarcomas |
| Q42384507 | Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma |
| Q37103609 | Experimental non-ATP-competitive therapies for chronic myelogenous leukemia |
| Q42930980 | Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells |
| Q46767452 | HCV infection and cryptogenic cirrhosis are risk factors for hepatocellular carcinoma among Latinos in New York City |
| Q37303196 | HER2 breast cancer therapies: a review |
| Q29617504 | HSP90 and the chaperoning of cancer |
| Q36429542 | HSP90: a rising star on the horizon of anticancer targets |
| Q30585904 | Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis |
| Q35762499 | Heat shock protein 90 inhibition in lung cancer |
| Q30418761 | Heat shock protein 90 inhibition: rationale and clinical potential |
| Q35051987 | Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells |
| Q34164027 | Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions |
| Q33998634 | Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells |
| Q38085897 | Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets |
| Q37709711 | Heat shock proteins as targets in oncology |
| Q37107963 | Heat shock proteins in animal neoplasms and human tumours--a comparison |
| Q48596233 | Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics? |
| Q34400894 | Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo |
| Q37690758 | Hsp90 as a therapeutic target in patients with oesophageal carcinoma |
| Q28542000 | Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation |
| Q92344661 | Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry |
| Q38089906 | Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins |
| Q28474354 | Induction of premature senescence by hsp90 inhibition in small cell lung cancer |
| Q36336624 | Inhibiting induction of heat shock proteins as a strategy to enhance cancer therapy |
| Q34654791 | Inhibition of HSP90 molecular chaperones: moving into the clinic |
| Q47770721 | Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature |
| Q28541342 | Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer |
| Q37130217 | Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma |
| Q37827173 | Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers |
| Q37225282 | Involvement of calcium-mediated reactive oxygen species in inductive GRP78 expression by geldanamycin in 9L rat brain tumor cells |
| Q41827236 | Irradiation facilitates the inhibitory effect of the heat shock protein 90 inhibitor NVP-BEP800 on the proliferation of malignant glioblastoma cells through attenuation of the upregulation of heat shock protein 70. |
| Q39894584 | Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins |
| Q35017513 | Macrocyclic inhibitors of hsp90 |
| Q28272747 | Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy |
| Q42879480 | Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP |
| Q36979035 | Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. |
| Q56355675 | Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum |
| Q36495265 | Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein |
| Q36311166 | Multifocal angiostatic therapy: an update |
| Q33235403 | Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). |
| Q36532080 | New molecular targets in advanced prostate cancer |
| Q37813152 | Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors |
| Q43410223 | Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors |
| Q28278381 | Pharmacodynamic biomarkers for molecular cancer therapeutics |
| Q37386171 | Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia |
| Q53569824 | Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. |
| Q37437264 | Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen |
| Q34085148 | Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors |
| Q33388351 | Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors |
| Q35751885 | Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. |
| Q37594553 | Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies |
| Q35469572 | Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer |
| Q37068863 | Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. |
| Q40274520 | Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. |
| Q38065103 | Recent updates on the development of ganetespib as a Hsp90 inhibitor |
| Q35676153 | Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation |
| Q46940974 | Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia |
| Q41987459 | Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex |
| Q37071103 | SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK |
| Q35469447 | SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers |
| Q36879064 | Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. |
| Q34636939 | Structural basis for depletion of heat shock protein 90 client proteins by deguelin. |
| Q36501393 | Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles |
| Q45079863 | Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites |
| Q38909847 | Synthesis and biological evaluation of geldanamycin analogs against human cancer cells. |
| Q33390600 | Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study |
| Q36162690 | Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma |
| Q37494634 | Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. |
| Q36450785 | Targeted approaches for the management of metastatic prostate cancer |
| Q46947497 | Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. |
| Q37882456 | Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II. |
| Q28288602 | Targeting the dynamic HSP90 complex in cancer |
| Q38191794 | Targeting tumour-supportive cellular machineries in anticancer drug development |
| Q26824363 | The G protein α chaperone Ric-8 as a potential therapeutic target |
| Q38358625 | The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. |
| Q33697116 | The multiple facets of drug resistance: one history, different approaches |
| Q39948991 | The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells |
| Q39401044 | The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases |
| Q41656985 | The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining |
| Q36499222 | Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology |
| Q35009729 | Update on Hsp90 inhibitors in clinical trial. |
| Q38780512 | β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis |
Search more.